05 January 2017

BICYCLE THERAPEUTICS APPOINTS NICHOLAS KEEN, PH.D., AS CHIEF SCIENTIFIC OFFICER

 

CAMBRIDGE, MASS. and CAMBRIDGE, U.K. – Bicycle Therapeutics, a biotechnology company pioneering a new class of therapeutics based on its proprietary bicyclic peptide (Bicycle®) product platform, announced today the appointment of Nicholas Keen, Ph.D., as Chief Scientific Officer.

“Nick is a highly experienced oncology drug hunter and has great experience leading cancer drug discovery programs at the highest level in top biopharmaceutical companies. He has championed novel mechanisms and progressed multiple compounds into the clinic that will benefit cancer patients. This appointment is further validation of the transformative value of the Bicycle platform and builds on the exciting collaborations we announced with AstraZeneca and Cancer Research UK at the end of last year, as well as our Fierce Innovation Award for best drug delivery technology.”

Kevin Lee, Ph.D

Bicycle’s Chief Executive Officer.

“I am excited to join Bicycle at this pivotal time in the company’s development. Bicycle’s technology possesses great potential – Bicycles are a completely new class of drugs that combine the rapid selection, affinity and selectivity of antibodies with properties of small molecules.I look forward to guiding efforts to leverage the strength and breadth of this technology, including a core oncology portfolio that has already delivered the first Bicycle Drug Conjugateinto preclinical development.”

Dr. Keen

“We are thrilled to welcome Nick to Bicycle’s leadership team and believe his expertise will prove invaluable as we continue to progress our U.K.-centred novel product platform and build our U.S.-based oncology hub.”

Rosamond Deegan

Bicycle’s U.S. President and Chief Business Officer

About Bicycle Therapeutics

Bicycle Therapeutics is developing a new class of medicines to treat oncology and other debilitating diseases based on its proprietary bicyclic peptide (Bicycle®) product platform. Bicycles® exhibit an affinity and exquisite target specificity usually associated with antibodies, whilst a low molecular weight delivers rapid and deep tissue penetration enabling more efficient tumour targeting. Their peptidic nature provides a “tuneable” pharmacokinetic half-life and a renal route of clearance, avoiding the liver and gastrointestinal tract toxicities often seen with other drug modalities. Bicycle Therapeutics is rapidly advancing towards the clinic with its lead molecule, BT1718 and is collaborating in oncology and other areas to realise the full potential of the technology. Bicycle Therapeutics’ unique intellectual property is based on the work initiated at the MRC Laboratory of Molecular Biology in Cambridge, U.K., by the scientific founders of the company, Sir Gregory Winter and Professor Christian Heinis. Bicycle Therapeutics is headquartered in Cambridge, U.K., with a U.S. subsidiary in Cambridge, Massachusetts. For more information, visit www.bicycletherapeutics.com

Contacts:

Ten Bridge Communications (U.S.)
Sarah Sutton
Sarah@tenbridgecommunications.com
+1-857-242-1619 

Consilium Strategic Communications (EU)
Mary-Jane Elliott / Chris Gardner / Ivar Milligan
Bicycle@consilium-comms.com
+44 20 3709 5700


Back to previous page